Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

Jing Ni¹, Yanzhi Wang¹, Irmina Dials¹, Sheheryar Kabraji¹, Rachel A. Freedman¹, Nancy U. Lin¹, Jean J. Zhao¹.
¹Dana-Farber Cancer Institute, Boston, MA. ²Puma Biotechnology, Los Angeles, CA, USA.

Abstract
Up to half of patients with metastatic HER2-positive breast cancer will develop brain metastases. Breast cancer brain metastases (BCBM) are a major cause of morbidity and mortality, despite multimodal management including surgery, radiotherapy, and systemic therapies. Therefore, there is an urgent need to develop novel, efficacious alternatives. Neratinib is an orally bioavailable, irreversible pan-HER tyrosine kinase inhibitor that is FDA-approved in the extended adjuvant treatment setting for HER2-positive, early breast cancer (NCT00878709). Neratinib has only modest activity as a single agent in clinical trials of patients with HER2-positive brain metastases. Though the combination of neratinib and capcitabine results in CNS responses in up to half of patients, patients eventually develop drug resistance, and toxicities have been a concern (TBCRC022), thus exploration of alternative neratinib combinations is of significant clinical interest. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate with reported single-agent activity against HER2-positive BCBM. Here, we used HER2-positive orthotopic patient derived xenograft (PDX) models of BCBM to test if combining neratinib with T-DM1 could improve tumor response. PDX cells are labelled with luciferase to allow tumor growth measurement in vivo. We found that neratinib is able to reduce phosphorylated HER2 in an orthotopic PDX tumor derived from HER2-positive BCBM, indicating that neratinib can cross the BBB and inhibit HER2 activation in BCBM PDX tissues. However, in both HER2-positive DF-BM354 and DF-BM355 PDX models, single agent neratinib did not block orthotopic tumor growth compared to vehicle control as monitored by bioluminescence measurements. In contrast, combined treatment of neratinib with T-DM1 significantly reduced tumor growth compared to single agent treatment with neratinib or T-DM1 at earlier time points in both models. At later time points, the combined treatment is comparable to T-DM1 alone in DF-BM354 model, but significantly prolong the survival of mice bearing DF-BM355 tumors. These data warrant further testing of neratinib alone and in combination with T-DM1 in additional BCBM PDX models to better understand drivers of resistance and susceptibility to HER2-inhibitors in HER2-positive BCBMs. Furthermore, they support the launch of a prospective clinical trial (NCT01494662) to test the efficacy and tolerability of T-DM1 in combination with neratinib in patients with progressive HER2-positive BCBM.

Results
Modeling metastatic breast cancer to brain

Orthotopic BCBM PDXs resemble the original patient BCBM at the genomic, histopathological, and molecular levels (Ni et al 2016 Nature Medicine).

Acknowledgements
NIH/NCI; The Stand Up to Cancer; Breast Cancer Research Foundation; PUMA biotechnology